论文部分内容阅读
目的探讨重症监护室(ICU)心力衰竭患者应用右美托咪定治疗的临床疗效。方法选取我院2015年3月至2017年3月进入ICU治疗的心力衰竭患者共60例,将其均分为研究组和对照组进行研究,其中前者选用右美托咪定治疗,后者则用丙泊酚进行治疗,对比两组治疗前后肌酸激酶(CK-MB)、肌红蛋白(MYO)、Pa CO2以及APACHEⅡ评分和Ramsay评分变化情况。结果与入ICU时相比,两组患者24h后的CK-MB、MYO、Pa CO2均降低了,且研究组24h后以上三个指标均低于对照组,差异有统计学意义(P<0.05);经治疗后,与对照组相比,研究组APACHEⅡ评分与Ramsay评分都低于前者,差异显著(P<0.05)。结论应用右美托咪定治疗ICU心力衰竭患者可对心肌功能进行有效恢复,从而缓解患者心力衰竭症状,有利于患者预后的改善。
Objective To investigate the clinical efficacy of dexmedetomidine in patients with intensive care unit (ICU) heart failure. Methods A total of 60 patients with heart failure admitted to ICU from March 2015 to March 2017 in our hospital were selected and divided into two groups: study group and control group. The former was treated with dexmedetomidine and the latter was treated with dexmedetomidine Propofol was used to treat the changes of creatine kinase (CK-MB), myoglobin (MYO), PaCO 2, APACHEⅡand Ramsay scores before and after treatment. Results Compared with ICU, the CK-MB, MYO and Pa CO2 in both groups decreased after 24h, and the above three indexes in study group were lower than those in control group after 24 hours, the difference was statistically significant (P <0.05 ); After treatment, compared with the control group, APACHE Ⅱ score and Ramsay score of the study group were lower than the former, the difference was significant (P <0.05). Conclusion Dexmedetomidine treatment of ICU patients with heart failure can be an effective recovery of myocardial function, thereby relieving the symptoms of heart failure, is conducive to the prognosis of patients with improvement.